Emerging Role of Flavonoids as the Treatment of Depression
Depression is one of the most frequently observed psychological disorders, affecting thoughts, feelings, behavior and a sense of well-being in person. As per the WHO, it is projected to be the primitive cause of various other diseases by 2030. Clinically, depression is treated by various types of synthetic medicines that have several limitations such as side-effects, slow-onset action, poor remission and response rates due to complicated pathophysiology involved with depression. Further, clinically, patients cannot be given the treatment unless it affects adversely the job or family. In addition, synthetic drugs are usually single targeted drugs. Unlike synthetic medicaments, there are many plants that have flavonoids and producing action on multiple molecular targets and exhibit anti-depressant action by affecting multiple neuronal transmissions or pathways such as noradrenergic, serotonergic, GABAnergic and dopaminergic; inhibition of monoamine oxidase and tropomyosin receptor kinase B; simultaneous increase in nerve growth and brain-derived neurotrophic factors. Such herbal drugs with flavonoids are likely to be useful in patients with sub-clinical depression. This review is an attempt to analyze pre-clinical studies, structural activity relationship and characteristics of reported isolated flavonoids, which may be considered for clinical trials for the development of therapeutically useful antidepressant..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Biomolecules - 11(2021), 12, p 1825 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arzoo Pannu [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Anti-depressants |
|---|
| doi: |
10.3390/biom11121825 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ01417328X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ01417328X | ||
| 003 | DE-627 | ||
| 005 | 20240412095423.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/biom11121825 |2 doi | |
| 035 | |a (DE-627)DOAJ01417328X | ||
| 035 | |a (DE-599)DOAJ538fb0398c394d42bed4a6b08b6f319e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QR1-502 | |
| 100 | 0 | |a Arzoo Pannu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging Role of Flavonoids as the Treatment of Depression |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Depression is one of the most frequently observed psychological disorders, affecting thoughts, feelings, behavior and a sense of well-being in person. As per the WHO, it is projected to be the primitive cause of various other diseases by 2030. Clinically, depression is treated by various types of synthetic medicines that have several limitations such as side-effects, slow-onset action, poor remission and response rates due to complicated pathophysiology involved with depression. Further, clinically, patients cannot be given the treatment unless it affects adversely the job or family. In addition, synthetic drugs are usually single targeted drugs. Unlike synthetic medicaments, there are many plants that have flavonoids and producing action on multiple molecular targets and exhibit anti-depressant action by affecting multiple neuronal transmissions or pathways such as noradrenergic, serotonergic, GABAnergic and dopaminergic; inhibition of monoamine oxidase and tropomyosin receptor kinase B; simultaneous increase in nerve growth and brain-derived neurotrophic factors. Such herbal drugs with flavonoids are likely to be useful in patients with sub-clinical depression. This review is an attempt to analyze pre-clinical studies, structural activity relationship and characteristics of reported isolated flavonoids, which may be considered for clinical trials for the development of therapeutically useful antidepressant. | ||
| 650 | 4 | |a nutraceuticals | |
| 650 | 4 | |a depression | |
| 650 | 4 | |a flavonoids | |
| 650 | 4 | |a anti-depressants | |
| 650 | 4 | |a anti-oxidant | |
| 653 | 0 | |a Microbiology | |
| 700 | 0 | |a Prabodh Chander Sharma |e verfasserin |4 aut | |
| 700 | 0 | |a Vijay Kumar Thakur |e verfasserin |4 aut | |
| 700 | 0 | |a Ramesh K. Goyal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Biomolecules |d MDPI AG, 2013 |g 11(2021), 12, p 1825 |w (DE-627)DOAJ000114170 |x 2218273X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:12, p 1825 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/biom11121825 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/538fb0398c394d42bed4a6b08b6f319e |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2218-273X/11/12/1825 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2218-273X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 12, p 1825 | ||